文献速递药物相互作用

GLPG3970对柳氮磺吡啶和甲氨蝶呤药代动力学的影响:两项健康成人开放标签I期药物相互作用研究

Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open-Label, Phase I, Drug-Drug Interaction Studies.
PubMed 文献 · Clin Pharmacol Ther · 2024-11-08

两项开放标签、非随机、I期药物相互作用研究评估了GLPG3970 350 mg对柳氮磺吡啶(SSZ)1000 mg和甲氨蝶呤(MTX)7.5 mg药代动力学的影响。结果显示,GLPG3970联合SSZ使SSZ暴露增加约1.7-1.8倍,SPD:SSZ比值降低约2倍,而SSZ后2小时给予GLPG3970未改变相互作用程度;GLPG3970联合MTX对MTX药代动力学无相关影响。

要点

  • GLPG3970轻度抑制肠道BCRP,使SSZ暴露增加约1.7-1.8倍。
  • SSZ后2小时给予GLPG3970未改变相互作用程度。
  • GLPG3970对MTX药代动力学无相关影响。

核心结论

  • GLPG3970在体内表现为轻度肠道BCRP抑制,未证实体外强抑制作用。
  • GLPG3970与SSZ或MTX联用未观察到安全性问题。

研究设计与样本

  • 两项开放标签、非随机、I期药物相互作用研究。
  • SSZ/GLPG3970研究纳入8例健康受试者,MTX/GLPG3970研究纳入15例健康受试者。
  • 受试者年龄18-55岁,BCRP基因型为野生型纯合子(c421C/C)。

主要发现

  • GLPG3970+SSZ使SSZ暴露增加约1.7-1.8倍,SPD:SSZ比值降低约2倍(vs SSZ单用)。
  • SSZ后2小时给予GLPG3970未改变相互作用程度。
  • GLPG3970+MTX对MTX药代动力学无相关影响(vs MTX单用)。

关键数值与推荐

  • SSZ或MTX暴露增加>2倍视为具有临床相关性。

临床怎么用

  • GLPG3970与SSZ联用时应关注SSZ暴露增加可能带来的安全性风险。
  • GLPG3970与MTX联用无需调整MTX剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

GLPG3970 is a selective salt-inducible kinase 2/3 inhibitor intended for the treatment of inflammatory diseases. In vitro studies suggest GLPG3970 strongly inhibits breast cancer resistance protein (BCRP), indicating a possible interaction with BCRP substrates such as sulfasalazine (SSZ; a probe substrate for intestinal BCRP inhibition) and methotrexate (MTX), both inflammatory disease medications. Two open-label, nonrandomized, phase I, drug-drug interaction (DDI) studies assessed the pharmacokinetics of SSZ 1,000 mg (NCT04720183) and MTX 7.5 mg (EudraCT: 2020-000391-37) with and without GLPG3970 350 mg. Healthy participants aged 18-55 years with wild-type homozygous BCRP genotype (c421C/C) received: SSZ on day (D)1, GLPG3970 + SSZ on D5, and GLPG3970 2 hours after SSZ on D9 (N = 8; SSZ/GLPG3970 DDI study); MTX on D1, GLPG3970 + MTX on D5, and GLPG3970 on D6-8 (N = 15; MTX/GLPG3970 DDI study). Primary end points were AUC and Cmax ("exposure") of SSZ and its metabolite (sulfapyridine [SPD]), SPD:SSZ AUC ratio (SSZ/GLPG3970 study), and AUC and Cmax ("exposure") of MTX (MTX/GLPG3970 study). DDIs were evaluated using the geometric mean ratio of each end point; a > 2-fold increase in SSZ or MTX exposure was deemed clinically relevant. GLPG3970 demonstrated mild inhibition of intestinal BCRP in vivo: GLPG3970 + SSZ increased SSZ exposure ~1.7-1.8-fold and decreased SPD:SSZ ratio ~ 2-fold vs. SSZ alone. GLPG3970 administered 2 hours after SSZ did not change the magnitude of the interaction. GLPG3970 + MTX had no relevant effect on MTX pharmacokinetics vs. MTX alone. Therefore, the strong in vitro BCRP inhibition was not confirmed in vivo. No safety concerns were observed when GLPG3970 was coadministered with SSZ or MTX.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. van der Plas M, Dao J, Zabela V, et al. Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open-Label, Phase I, Drug-Drug Interaction Studies. Clin Pharmacol Ther. 2024. PMID: 39513407. doi:10.1002/cpt.3438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。